Slew of data backs Regeneron med for gout

Regeneron has unleashed a torrent of promising late-stage safety and efficacy data on Arcalyst, teeing up a strong new regulatory filing backing its quest to market the drug against gout. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.